Johnson & Johnson Results: A Deep Dive into Q3 2024 Earnings

Tuesday, 15 October 2024, 10:46

Johnson & Johnson results reveal key insights from the Q3 2024 earnings report, showcasing a significant sales increase. The pharmaceutical giant reported $22.5 billion in sales despite a notable dip in GAAP earnings. JNJ stock news continues to be critical for investors understanding the company's performance.
Alphastreet
Johnson & Johnson Results: A Deep Dive into Q3 2024 Earnings

Overview of Johnson & Johnson Q3 2024 Earnings

Johnson & Johnson (NYSE: JNJ) reported its Q3 2024 earnings today. Highlighting a 5.2% year-over-year increase in sales, total revenue reached $22.5 billion. Nevertheless, there was a striking 37.5% decrease in GAAP earnings to $2.7 billion, with EPS falling 34% to $1.11.

Sales and Financial Expectations

Adjusted EPS showed a 9% decline to $2.42. Looking ahead, the firm expects reported sales for the full year 2024 to range between $88.4 billion to $88.8 billion, with adjusted EPS projected at $9.88 to $9.98.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Get the most reliable and up-to-date financial news with our curated selections. Subscribe to our newsletter for convenient access and enhance your analytical work effortlessly.

Subscribe